Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Apr 24, 2026

  • Corporate

Chugai Announces 2026 1st Quarter Results

TOKYO, April 24, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced its financial results for the first quarter of fiscal year 2026.

  • Core revenue of ¥321.7 billion (+11.5%), core operating profit of ¥163.3 billion (+17.1%), and core net income of ¥118.6 billion (+19.6%) were achieved with strong sales performance of domestic and overseas products, resulting in increased revenue and profit (all changes year-on-year)
  • New product launches and additional indications included the launch of Elevidys as Japan’s first regenerative medical product for Duchenne muscular dystrophy (DMD), and the approval of Lunsumio and Polivy combination therapy for additional indication of relapsed or refractory large B‑cell lymphoma
  • R&D activities progressed steadily across both early and late-stage development, including Chugai-originated projects, with progress on track to achieving the highest number of application plans ever
    • NXT007 suggested favorable tolerability in Part C of the Phase I/II NXTAGE study for Hemophilia A following direct switching from Hemlibra without washout period
    • Enspryng presented Phase III results in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at the 2026 American Academy of Neurology Annual Meeting, and is preparing for regulatory application within the year
  • Regarding products out-licensed to third parties, FoundayoTM(orforglipron), an oral GLP‑1 receptor agonist out‑licensed to Eli Lilly, has obtained U.S. approval as a treatment for obesity and is currently under regulatory review in more than 40 countries, including Japan and the European Union
Refer to the information below for details on the financial results:

Quarterly Reports / Finance Reports
https://www.chugai-pharm.co.jp/english/ir/reports_downloads/tanshin.html

Presentation Materials
In addition to Chugai’s business and financial performance, these materials provide updates on our research and development pipeline. Videos and scripts (including Q&A) will be made available at a later date.
https://www.chugai-pharm.co.jp/english/media/conference.html

[2026 First Quarter Results]
Core results (Billion JPY)
 2026 2025 % change

Revenue

321.7

 288.5 +11.5%
  Domestic sales 111.4 103.0 +8.2%
  Overseas sales 180.1 156.7 +14.9%
  Other revenue 30.2 28.7 +5.2%
Operating profit 163.3

139.5

 +17.1%
Net income 118.6 99.2 +19.6%

[PDF 141KB]

Back